To buy or not to buy? Samsung unit denies report about Biogen talks

During a mostly quiet news week for biopharma, Biogen and Samsung made waves Wednesday when the Korea Economic Daily reported that the Korean conglomerate was in talks to buy the Massachusetts biotech. Now, a unit of Samsung is adding another wrinkle to the story by denying the talks.

In a new disclosure, Samsung's global contract development and manufacturing organization Samsung Biologics responded to the news by saying the "information is not true." The move came after the Korea Economic Daily, citing "investment banking sources," reported Biogen approached Samsung about a sale and that the companies were negotiating a potential $42 billion deal.